瑞巴派特联合奥美拉唑对胃镜下糜烂性胃炎的影响  

Effect of chronic erosive gastritis patients treated with Rebamipide combined with Omeprazole

作　　者：伍早安 缪胜菊[2] 黄颖[3] 

机构地区：[1]解放军第457医院,430012 [2]湖北省新华医院 [3]部队门诊部,95829

出　　处：《中国医学创新》2010年第26期12-14,共3页Medical Innovation of China

摘　　要：目的探讨瑞巴派特联合舆美拉唑对糜烂性胃炎胃镜下糜烂愈合的改善情况。方法连续收集就诊患者70例纳入临床观察,随机分为治疗组(35例)和对照组(35例)。治疗组采用瑞巴派特联合奥美拉唑肠溶片口服治疗,对照组单用奥美拉唑肠溶片口服治疗,分别于治疗第2、3、4周观察临床症状改善情况及治疗前后胃镜下胃炎愈合情况。结果经过4周治疗,治疗组临床症状缓解率94.2%(P<0.05),对照组临床症状缓解率82.9%(P<0.05),而两组相比有显著性差异(P<0.05)。治疗结束后,对照组与治疗组胃镜下黏膜糜烂愈合有效率分别为80.0%和91.4%,后者有更高的黏膜愈合能力(P<0.05),两组均未见明显副作用。结论瑞巴派特联用奥美拉唑有利于慢性糜烂性胃炎黏膜糜烂的愈合及症状的改善。Objective To explore the efficacy of rebamipide and omeprazole in the treatment of the chronic erosive gastritis, and to evaluate the healing quality of erosion. Methods 70 patients with chronic erosive gastritis were divided into two groups randomly and equally. The control group was treated with omeprazole and the therapy greul~ was treated with rebam- ipide plus omeprazole. Both groups were treated for 4 successive weeks. The symptoms were assessed before and 2,3,4 weeks after the treatment, as well as endoscopic examination were conducted before and after the treatment. Results The total remis- sion rate of symptoms was 82.9% in the control group ,which was 94.2% in the therapy group. There was a significant differ- ence between two groups（ P 〈 0.05 ）. In addition, the recovery rate of mucosal erosion in the control group was 80.0%, and it was 91.4% in the therapy group. The latter got better recovery of mucosa. We did not found obvious side effects in both groups. Conclusion Rebamipide plus omeprazole is beneficial for recovery of erosive gastric mueosa and improvement of dyspepsia symptoms.

关 键 词：瑞巴派特 胃镜 糜烂性胃炎 黏膜糜烂 

分 类 号：R573.3[医药卫生—消化系统]